Lipodystrophy raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-12-11 and is reviewed periodically as new material appears.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Paddy Ryder's profile on the official website of the St Kilda Football Club Paddy Ryder's playing statistics from AFL Tables Paddy Ryder at AustralianFootball.com Paddy Ryder's WAFL playing statistics at WAFLFootyFacts.net
== Use == Carrel and Dakin used a variety of apparatuses to infuse the solution continuously over the wounds. In modern typical usage, the solution is applied to the wound once daily for lightly to moderately exudative wounds, and twice daily for heavily exudative wounds or highly contaminated wounds. The healthy skin surrounding the wound should preferably be protected with a moisture barrier ointment (e.g., petroleum jelly) or skin sealant as needed to prevent irritation.
Austin had guest roles on Celebrity Deathmatch and Seasons 4 and 5 of CBS's Nash Bridges, where he played San Francisco Police Department Inspector Jake Cage. He has appeared on V.I.P and Dilbert. His motion picture debut was in a supporting role as Guard Dunham in the 2005 remake of The Longest Yard. Austin had his first starring film role, as Jack Conrad, a dangerous convict awaiting execution in a Salvadoran prison, who takes part in an illegal deathmatch game that is being broadcast to the public in the 2007 action film The Condemned. In 2010, Austin appeared in The Expendables as Dan Paine, the right-hand man for the primary antagonist of the film James Munroe, played by Eric Roberts, and bodyguard with Gary Daniels who plays The Brit. Shortly after Austin re-teamed with Eric Roberts and Gary Daniels in Hunt to Kill. It was his last American theatrical release film until 2013. Austin appeared as Hugo Panzer on television series Chuck. He has also starred in Damage, The Stranger, Tactical Force, Knockout, Recoil, Maximum Conviction, and The Package. He made an appearance in Grown Ups 2 and his most recent acting role came in Smosh: The Movie. In 2011, a documentary was released about Austin's career titled Stone Cold Steve Austin: The Bottom Line on the Most Popular Superstar of All Time. It included interviews with Austin and his and his rivals while covering his most famous matches, promos, and behind-the-scenes moments.
==== Disorganized crime ==== The economist Peter Reuter has challenged the conventional framework of crime taking place in an organized manner with respect to drug trafficking. He argues that criminal organizations are unable to form monopolies and trend toward factionalism. Reuter and other skeptics have said that drug cartels and mafias are rhetorical constructs used by police and prosecutors to simplify a complex and heterogeneous criminal underworld that is in fact composed of smaller competing cliques and informal social networks.
== Low gravity == It has been observed that being in Earth's orbit has an effect on the structure of spider webs in space. Spider webs were spun in low Earth orbit in 1973 aboard Skylab, involving two female European garden spiders (cross spiders) called Arabella and Anita, as part of an experiment on the Skylab 3 mission. The aim of the experiment was to test whether the two spiders would spin webs in space, and, if so, whether these webs would be the same as those that spiders produced on Earth. The experiment was a student project of Judy Miles of Lexington, Massachusetts. After the launch on July 28, 1973, and entering Skylab, the spiders were released by astronaut Owen Garriott into a box that resembled a window frame. The spiders proceeded to construct their web while a camera took photographs and examined the spiders' behavior in a zero-gravity environment. Both spiders took a long time to adapt to their weightless existence. However, after a day, Arabella spun the first web in the experimental cage, although it was initially incomplete.
Sources: en.wikipedia.org
== History == Native American cultivators who first domesticated corn (maize) prepared it by nixtamalization, in which the grain is treated with a solution of alkali such as lime. Nixtamalization makes the niacin nutritionally available and prevents pellagra. When maize was cultivated worldwide, and eaten as a staple without nixtamalization, pellagra became common. Pellagra was first described for its dermatological effect in Spain in 1735 by Gaspar Casal. He explained that the disease causes dermatitis in exposed skin areas such as hands, feet, and neck and that the origin of the disease is poor diet and atmospheric influences. His work published in 1762 by his friend Juan Sevillano was titled Historia Natural y Medicina del Principado de Asturias or Natural and Medical History of the Principality of Asturias (1762). This led to the disease being known as "Asturian leprosy", and it is recognized as the first modern pathological description of a syndrome. It was an endemic disease in northern Italy, where it was named, from Lombard, by Francesco Frapolli of Milan (see #Etymology). With pellagra affecting over 100,000 people in Italy by the 1880s, debates raged as to how to classify the disease (as a form of scurvy, elephantiasis, or as something new) and over its causation. In the 19th century, Roussel started a campaign in France to restrict consumption of maize and eradicated the disease in France, but it remained endemic in many rural areas of Europe.
The association of a protein with a lipid bilayer may involve significant changes within tertiary structure of a protein. These may include the folding of regions of protein structure that were previously unfolded or a re-arrangement in the folding or a refolding of the membrane-associated part of the proteins. It also may involve the formation or dissociation of protein quaternary structures or oligomeric complexes, and specific binding of ions, ligands, or regulatory lipids. Typical amphitropic proteins must interact strongly with the lipid bilayer in order to perform their biological functions. These include the enzymatic processing of lipids and other hydrophobic substances, membrane anchoring, and the binding and transfer of small nonpolar compounds between different cellular membranes. These proteins may be anchored to the bilayer as a result of hydrophobic interactions between the bilayer and exposed nonpolar residues at the surface of a protein, by specific non-covalent binding interactions with regulatory lipids , or through their attachment to covalently bound lipid anchors. It has been shown that the membrane binding affinities of many peripheral proteins depend on the specific lipid composition of the membrane with which they are associated.
=== Prehistoric reptiles === Pterosaurian pycnofibrils strongly resemble mammalian hair, but are thought to have evolved independently. Ornithischian (bird-hipped) dinosaurs had a pelvis shape similar to that of birds, or avian dinosaurs, which evolved from saurischian (lizard-hipped) dinosaurs. The Heterodontosauridae evolved a tibiotarsus which is also found in modern birds. These groups are not closely related. Ankylosaurs and glyptodont mammals both had spiked tails. The sauropods and giraffes independently evolved long necks. The horned snouts of ceratopsian dinosaurs like Triceratops have also evolved several times in Cenozoic mammals: rhinos, brontotheres, Arsinoitherium, and Uintatherium. Rhynchosaur teeth resemble that of the extant rodents. Billed snouts on the duck-billed dinosaurs hadrosaurs are strikingly convergent with ducks and the duck-billed platypus. Ichthyosaurs (such as Ophthalmosaurus) are marine reptile of the Mesozoic era which looked strikingly like dolphins. Several groups of marine reptiles evolved hyperphalangy similar to modern whales. Toothless beaks are independently derived in ornithomimosaurian, alvarezsaurian, therizinosaurian, oviraptorosaurian and ceratopsian dinosaurs like Triceratops, certain pterosaurs, birds, turtles, and cephalopods like squid, cuttlefish, and octopus. The "Pelycosauria" and the Ctenosauriscidae bore striking resemblance to each other because they both had a sail-like fin on their back.
Shortly after, Jason sends an apology letter under the form of a comic strip to Ellie, who accepts the apology, and they start seeing each other on a regular basis. Meanwhile, Daniel begins to fall for Chelsea, and the two begin seeing one another. Additionally, Mikey meets with Vera, and when she claims that the reason their marriage fell apart is because he is not spontaneous enough, Mikey kisses her, and the two sleep together in the hospital, reigniting their romance. All three friends attempt to keep their relationships a secret, due to their earlier agreement that they would stay single. Jason steals a key to open the gates to Gramercy Park, then gives the key to Ellie. They sleep together again, and continue seeing each other. Ellie meets Mikey and Daniel, who both really like her, but they remind Jason of their deal. Jason then meets Ellie’s father at a party thrown by Ellie, and they get along really well. However, shortly after, Ellie’s father dies. The relationships all come to a head during Thanksgiving, a time that the three friends usually spend together, but varying circumstances keep them apart. Jason agrees to attend a funeral for Ellie's recently passed father, Mikey plans a Thanksgiving dinner with Vera, and Daniel attends the traditional Thanksgiving feast with Chelsea, free to openly tell the guests about their relationship. Jason ultimately decides not to attend the funeral, not ready to fully commit to Ellie, and their relationship falls apart.
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.